UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 177

Sortiert nach

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

2023

Volltextzugriff (PDF)

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases

Nature communications, 2018-07, Vol.9 (1), p.2705-18, Article 2705

2018

Volltextzugriff (PDF)

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1694-1704

2018

Volltextzugriff (PDF)

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Blood, 2021-02, Vol.137 (7), p.896-907

2021

Volltextzugriff (PDF)

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2308-2318

2020

Volltextzugriff (PDF)

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Molecular cancer research, 2020-09, Vol.18 (9), p.1278-1289

2020

Volltextzugriff (PDF)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Translational oncology, 2022-07, Vol.21, p.101440-101440, Article 101440

2022

Volltextzugriff (PDF)

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Frontiers in oncology, 2024, Vol.14, p.1386190-1386190

2024

Volltextzugriff (PDF)

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

Cell death & disease, 2022-04, Vol.13 (4), p.410-14, Article 410

2022

Volltextzugriff (PDF)

Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations

American journal of physiology. Heart and circulatory physiology, 2009-02, Vol.296 (2), p.H359-H369

2009

Volltextzugriff (PDF)

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma

Pigment cell and melanoma research, 2016-11, Vol.29 (6), p.643-655

2016

Volltextzugriff (PDF)

Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease

PloS one, 2016-03, Vol.11 (3), p.e0152007-e0152007

2016

Volltextzugriff (PDF)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003388

2021

Volltextzugriff (PDF)

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Molecular cancer research, 2017-08, Vol.15 (8), p.1096-1105

2017

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

Frontiers in veterinary science, 2022-12, Vol.9, p.1056408-1056408

2022

Volltextzugriff (PDF)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

BMC pulmonary medicine, 2018-07, Vol.18 (1), p.112-112, Article 112

2018

Volltextzugriff (PDF)

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1389-1395

2018

Volltextzugriff (PDF)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

Cancer medicine (Malden, MA), 2023-02, Vol.12 (4), p.4236-4249

2023

Volltextzugriff (PDF)

A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy

Pharmaceutics, 2021-06, Vol.13 (7), p.997

2021

Volltextzugriff (PDF)

Selumetinib in Children with Inoperable Plexiform Neurofibromas

The New England journal of medicine, 2020-04, Vol.382 (15), p.1430-1442

2020

Volltextzugriff (PDF)

Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter

American journal of kidney diseases, 2017-04, Vol.69 (4), p.553-554

2017

Volltextzugriff (PDF)

Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012-06, Vol.898, p.32-37

2012

Volltextzugriff (PDF)

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Seminars in oncology, 2024-02, Vol.51 (1-2), p.19-24

2024

Volltextzugriff (PDF)

1 – 25 von 177

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Cancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(171)
Mit Volltextzugriff
(166)

Publikationsform

Sprache

Englisch
(177)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter

Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Aktive Filter

Suchergebnisse filtern